Skip to Main Content

Paper Details

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.
Int J Radiat Oncol Biol Phys
13
2022
BCS, Breast Cancer, HER2, HER2-Positive Breast Cancer, HER2-positive breast cancer, Human epidermal growth factor receptor 2, Paclitaxel, Patients, Skin toxicity, T, T-DM1, TH, Trastuzumab, Trastuzumab Emtansine, Women, mastectomy, paclitaxel, patients, plus trastuzumab, pneumonitis, skin, trastuzumab, trastuzumab emtansine, women
Author NameAffiliation
Steven J IsakoffHarvard Medical School, Massachusetts General Hospital
Eric P WinerHarvard Medical School, Dana-Farber Cancer Institute
Ian E KropHarvard Medical School, Dana-Farber Cancer Institute
Sara M TolaneyHarvard Medical School, Dana-Farber Cancer Institute
  • 1 - 4

Datasets

Release 1.2